• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Turns Higher; Akumin Shares Jump

    10/23/23 12:06:10 PM ET
    $AKU
    $APLM
    $INVO
    $LICY
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKU alert in real time by email

    U.S. stocks pared losses midway through trading, with the Nasdaq Composite gaining over 60 points on Monday.

    The Dow traded down 0.01% to 33,126.50 while the NASDAQ rose 0.54% to 13,054.00. The S&P 500 also rose, gaining, 0.29% to 4,236.55.

    Check This Out: This Analyst With 85% Accuracy Rate Sees More Than 42% Upside In Amazon.com - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

     

    Leading and Lagging Sectors

     

    Communication services shares rose by 0.9% on Monday.

    In trading on Monday, energy shares dipped by 1%.

     

    Top Headline

     

    The Chicago Fed National Activity Index climbed to +0.02 in September versus a revised reading of -0.22 in the prior month.

     

    Equities Trading UP

     

    LumiraDx Limited (NASDAQ:LMDX) shares shot up 205% to $0.2650 after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-based heart and lung screening hub.

    Shares of INVO Bioscience, Inc. (NASDAQ:INVO) got a boost, shooting 337% to $2.36 as the company agreed to acquire NAYA Biosciences in an all-stock transaction.

    Akumin Inc. (NASDAQ:AKU) shares were also up, gaining 154% to $0.3703 after the company reached an agreement with Stonepeak to become a private company.

     

    Equities Trading DOWN

     

    Li-Cycle Holdings Corp. (NYSE:LICY) shares dropped 42% to $1.3082 after the company announced plans to halt construction work on its Rochester Hub project, pending completion of a comprehensive review of the go-forward strategy for the project..

    Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) were down 43% to $16.00 after the company announced it presented clinical activity and safety data from its Phase 1/1b trial of RMC-6236.

    Apollomics, Inc. (NASDAQ:APLM) was down, falling 40% to $1.04 after the company announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at ESMO 2023.

    Also Check This Out: Top 4 Consumer Stocks That May Crash This Quarter

     

    Commodities

     

    In commodity news, oil traded down 2% to $86.39 while gold traded down 0.3% at $1,988.50.

    Silver traded down 1.2% to $23.225 on Monday while copper rose 0.4% to $3.5765.

     

    Euro zone

     

    European shares were mixed today. The eurozone’s STOXX 600 fell 0.12%, London’s FTSE 100 fell 0.36% while Spain’s IBEX 35 Index fell 0.41% The German DAX fell 0.03% French CAC 40 rose 0.51%, while Italy’s FTSE MIB Index gained 0.80%.

     

    Asia Pacific Markets

     

    Asian markets closed lower on Monday, with Japan’s Nikkei 225 falling 0.83% and China’s Shanghai Composite Index falling 1.47%. India’s S&P BSE Sensex, meanwhile, fell 0.8%.

    Food prices in Singapore rose by 4.3% year-over-year in September following a 4.8% increase in August. Singapore's annual inflation rate rose to 4.1% in September from August's level of 4.0%.

     

    Economics

     

    The Chicago Fed National Activity Index climbed to +0.02 in September versus a revised reading of -0.22 in the prior month.

    Now Read This: $15M Bet On Day One Biopharmaceuticals? Check Out These 3 Stocks Insiders Are Buying

    Get the next $AKU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKU
    $APLM
    $INVO
    $LICY

    CompanyDatePrice TargetRatingAnalyst
    Revolution Medicines Inc.
    $RVMD
    7/16/2024$46.00 → $62.00Buy
    Needham
    Revolution Medicines Inc.
    $RVMD
    7/12/2024$52.00Overweight
    Barclays
    Revolution Medicines Inc.
    $RVMD
    7/8/2024$63.00Buy
    Jefferies
    Revolution Medicines Inc.
    $RVMD
    4/12/2024$36.00 → $46.00Buy
    Needham
    Revolution Medicines Inc.
    $RVMD
    4/10/2024$36.00 → $48.00Outperform → Strong Buy
    Raymond James
    Revolution Medicines Inc.
    $RVMD
    3/11/2024$43.00Overweight
    Piper Sandler
    Revolution Medicines Inc.
    $RVMD
    1/5/2024$31.00 → $34.00Neutral → Buy
    BofA Securities
    Revolution Medicines Inc.
    $RVMD
    1/4/2024$41.00Outperform
    Wedbush
    More analyst ratings

    $AKU
    $APLM
    $INVO
    $LICY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham reiterated coverage on Revolution Medicines with a new price target

      Needham reiterated coverage of Revolution Medicines with a rating of Buy and set a new price target of $62.00 from $46.00 previously

      7/16/24 8:15:42 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barclays initiated coverage on Revolution Medicines with a new price target

      Barclays initiated coverage of Revolution Medicines with a rating of Overweight and set a new price target of $52.00

      7/12/24 7:33:26 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Revolution Medicines with a new price target

      Jefferies initiated coverage of Revolution Medicines with a rating of Buy and set a new price target of $63.00

      7/8/24 8:13:53 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AKU
    $APLM
    $INVO
    $LICY
    SEC Filings

    See more
    • SEC Form 10-Q filed by Revolution Medicines Inc.

      10-Q - Revolution Medicines, Inc. (0001628171) (Filer)

      5/7/25 4:10:24 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Revolution Medicines, Inc. (0001628171) (Filer)

      5/7/25 4:05:10 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Revolution Medicines Inc.

      DEFA14A - Revolution Medicines, Inc. (0001628171) (Filer)

      4/29/25 4:39:20 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AKU
    $APLM
    $INVO
    $LICY
    Financials

    Live finance-specific insights

    See more
    • Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

      Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this yearNew non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio support strategies for first-line metastatic and earlier lines of treatmentAnthony Mancini joins as chief global commercialization officerRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial

      5/7/25 4:02:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live web

      4/30/25 4:05:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

      Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancerCompany anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of treatment for pancreatic cancer in the second half of 2025Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NA

      2/26/25 4:02:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AKU
    $APLM
    $INVO
    $LICY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

      Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this yearNew non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio support strategies for first-line metastatic and earlier lines of treatmentAnthony Mancini joins as chief global commercialization officerRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial

      5/7/25 4:02:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live web

      4/30/25 4:05:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barbara Weber, M.D., Elected to ITM Supervisory Board

      Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its Supervisory Board, effective May 01, 2025. The election occurred at ITM's Extraordinary General Meeting. Dr. Weber is the President, Chief Executive Officer and Founder of Tango Therapeutics (NASDAQ:TNGX). She has over 25 years of executive and research and development leadership experience in biotech, venture capital and at major pharmaceutical companies, including Novartis (NYSE:NVS) and GlaxoSmithKline (NYSE:GSK). ITM's Supervisory Board and the company overall will benefit from Dr. Weber's deep ex

      4/9/25 5:00:00 AM ET
      $BNTX
      $GSK
      $NVS
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $AKU
    $APLM
    $INVO
    $LICY
    Leadership Updates

    Live Leadership Updates

    See more
    • Nano One Announces Resignation of Paul Matysek and Appointment of Industry Veteran Anthony Tse as New Chair of the Board of Directors

      VANCOUVER, BC / ACCESSWIRE / October 1, 2024 / (TSX:NANO)(OTC:NNOMF)(Frankfurt:LBMB)Nano One® Materials Corp. ("Nano One" or the "Company"), a clean technology company with a patented process for the low-cost, low-GHG production of lithium-ion battery cathode active materials (CAM), is pleased to announce that Mr. Anthony Tse has been appointed Chair of the Board of Directors.Mr. Tse will succeed Paul Matysek, who is the founding Chair of Nano One and resigning as part of a planned transition to an advisory role that supports the incoming Chair and Board. Mr. Matysek is honoured to have presided over Nano One's growth and leadership for more than a decade."On behalf of Nano One and our share

      10/1/24 3:05:00 AM ET
      $BEN
      $LICY
      Investment Managers
      Finance
      Environmental Services
      Industrials
    • Li-Cycle Selects Marcum Canada LLP as its New Independent Auditor

      Li-Cycle to hold reconvened shareholder meeting on October 15, 2024 at 8:30 a.m. (EDT) to vote on appointment of new auditor Li-Cycle Holdings Corp. (NYSE:LICY) ("Li-Cycle" or the "Company"), a leading global lithium-ion battery resource recovery company, announced today that the Audit Committee of the Company's Board of Directors (the "Board") has unanimously approved the selection of Marcum Canada LLP ("Marcum") as the Company's independent registered public accounting firm that will serve as its independent auditor and the Board has approved that the appointment of Marcum be put forward for shareholder approval. "After careful consideration of offers and a comprehensive review of the

      8/9/24 6:00:00 AM ET
      $LICY
      Environmental Services
      Industrials
    • Li-Cycle Appoints Craig Cunningham as Chief Financial Officer

      Senior finance leader with deep public company, battery materials, and mining experience to lead financial initiatives in a permanent capacity Li-Cycle Holdings Corp. (NYSE:LICY) ("Li-Cycle" or the "Company"), a leading global lithium-ion battery resource recovery company, is pleased to announce that it has appointed Craig Cunningham to the role of Chief Financial Officer (CFO), effective July 20, 2024. Mr. Cunningham has served as Li-Cycle's interim CFO since March 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240718508433/en/Craig Cunningham (Photo: Business Wire) Mr. Cunningham brings nearly two decades of experience

      7/18/24 7:00:00 AM ET
      $ELBM
      $KGC
      $LICY
      Industrial Machinery/Components
      Miscellaneous
      Precious Metals
      Basic Materials

    $AKU
    $APLM
    $INVO
    $LICY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Clyburn Frank

      4/A - Revolution Medicines, Inc. (0001628171) (Issuer)

      4/28/25 6:27:35 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • General Counsel Cislini Jeff sold $79,008 worth of shares (2,041 units at $38.71), decreasing direct ownership by 3% to 57,723 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      3/24/25 4:55:57 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • General Counsel Cislini Jeff sold $56,921 worth of shares (1,458 units at $39.04), decreasing direct ownership by 2% to 59,764 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      3/19/25 5:43:42 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AKU
    $APLM
    $INVO
    $LICY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Li-Cycle Holdings Corp.

      SC 13D/A - Li-Cycle Holdings Corp. (0001828811) (Subject)

      12/9/24 6:03:27 PM ET
      $LICY
      Environmental Services
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Revolution Medicines Inc.

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      11/8/24 10:52:39 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Li-Cycle Holdings Corp.

      SC 13D/A - Li-Cycle Holdings Corp. (0001828811) (Subject)

      10/15/24 4:30:29 PM ET
      $LICY
      Environmental Services
      Industrials

    $AKU
    $APLM
    $INVO
    $LICY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schroeder Thilo bought $59,999,962 worth of shares (1,304,347 units at $46.00) (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      12/9/24 4:15:16 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Wellings Mark bought $9,031 worth of shares (6,250 units at $1.45), increasing direct ownership by 6% to 110,908 units (SEC Form 4)

      4 - Li-Cycle Holdings Corp. (0001828811) (Issuer)

      9/17/24 4:05:04 PM ET
      $LICY
      Environmental Services
      Industrials